Dr Emma Morris

Photo

Personal Profile

Name: Emma Morris Email: e.morris@ucl.ac.uk
Title: Dr Tel: +44 (0) 20 7794 0500 ext 33741
Department: Research Department of Immunology Fax: +44 (0) 20 7433 1943
Position: Reader in Immunology and Immunotherapy Address: Department of Immunolgy, UCL Medical School, Royal Free Campus, Royal Free Hospital, London, NW3 2PF
Research Domain: Cancer, Experimental Medicine, Infection, Immunology & Inflammation, Personalised Medicine, Stem Cells & Regenerative Medicine (Frontier Disciplines) Web Page: Personal Web Page

Profile

Research Description

* Novel approaches for generation of antigen-specific T cells for leukaemia and cancer immunotherapy. * Retroviral gene transfer of T cell receptor (TCR) genes into T cells and haematopoietic stem cells to re-direct antigen-specificity. * The generation of MHC class I-restricted tumour antigen-specific CD4+ helper T cells to augment CD8+ T cell mediated tumour immunotherapy. * Analysis of functional avidity and signalling pathways of tumour antigen-specific TCRs. * Investigation of the role of the CD8 co-receptor in TCR transduced CD4+ helper T cells and conventional CD8+ T cells. * The generation of pre-clinical models for the evaluation of WT1-specific immunotherapy (WT1 is a tumour associated antigen over-expressed in myelodysplasia (MDS), leukaemias (AML, CML), breast, ovarian, prostate and colon cancers. * Isolation of TCRs from T cell clones specific for tumour antigens. * Generation of antigen-specific regulatory T cells using TCR gene transfer.

Research Activities

Gene and Cellular Therapy of Haematological Malignancies

Education Description

Member of Panel of Examiners for Haematology FRCPath, Royal College of Pathologists, UK. Educational supervisor to two CMT doctors (Acute Medicine, UCLH). Bone Marrow Transplant and Immunology/Immunotherapy lecturer for North Thames London Haematology SPR Rotation Trainees. Regular teaching (lectures) of UCL BSc and MSc students and Medical Students (UCL Medical School). UCL iBSc and MSc student supervision for lab-based research projects (2 students/year). Regular teaching of Junior Doctors (UCLH) in Bone Marrow Transplant Clinics at UCLH NHS Trust. Educational Supervisor for Haematology Specialist Registrars training on the UCLH/RFH Haematology SpR Rotation. UCLH Haematology SpR Rotation Mentor

UCL Collaborators

Prof Hans Stauss; Prof Adrian Thrasher; Prof Paul Griffiths; Dr Karl Peggs; Prof Samuel Janes

External Collaborators

Publications

    2014

    • Chen Y, Ayaru L, Mathew S, Morris E, Pereira SP, Behboudi S (2014). Expansion of Anti-Mesothelin Specific CD4(+) and CD8(+) T Cell Responses in Patients with Pancreatic Carcinoma.. PLoS One, 9(2), e88133 - . doi:10.1371/journal.pone.0088133
    • Kothari J, Peggs KS, Bird A, Thomson KJ, Morris E, Virchis AE, Lambert J, Goldstone AH, Linch DC, Ardeshna KM (2014). Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.. Br J Haematol, , - . doi:10.1111/bjh.12741
    • Uttenthal B, Martinez-Davila I, Ivey A, Craddock C, Chen F, Virchis A, Kottaridis P, Grimwade D, Khwaja A, Stauss H, Morris EC (2014). Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.. Br J Haematol, 164(3), 366 - 375. doi:10.1111/bjh.12637

    2013

    • Dickinson RE, Milne P, Jardine L, Zandi S, Swierczek SI, McGovern N, Cookson S, Ferozepurwalla Z, Langridge A, Pagan S, Gennery A, Heiskanen-Kosma T, Hämäläinen S, Seppänen M, Helbert M, Tholouli E, Gambineri E, Reykdal S, Gottfreðsson M, Thaventhiran JE, Morris E, Hirschfield G, Richter AG, Jolles S, Bacon CM, Hambleton S, Haniffa M, Bryceson Y, Allen C, Prchal JT, Dick JE, Bigley V, Collin M (2013). The evolution of cellular deficiency in GATA2 mutation.. Blood, , - . doi:10.1182/blood-2013-07-517151
    • Field A-C, Vink C, Gabriel R, Al-Subki R, Schmidt M, Goulden N, Stauss H, Thrasher A, Morris E, Qasim W (2013). Comparison of Lentiviral and Sleeping Beauty Mediated αβ T Cell Receptor Gene Transfer. PLoS ONE, 8(6), - .
    • Qasim W, Brunetto M, Gehring A, Xue S-A, Zhan H, Ciccorossi P, Gilmour K, Swift S, Himoudi N, Cavallone D, Moriconi F, Farzhenah F, Mazzoni A, Chan L, Morris E, Thrasher A, Maini M, Bonino F, Staus H, Bertoletti A (2013). Production and use of autologous gene modified T cells targeting metastatic hepatitis B associated hepatocellular carcinoma.
    • Alsubki R, Field A-C, Hirwarkar P, Saudemont A, Stauss H, Morris E, Thrasher A, Pule M, Qasim W (2013). Engineering cord blood T cells for tumour immunotherapy.
    • Townsend WM, Holroyd A, Pearce R, Mackinnon S, Naik P, Goldstone AH, Linch DC, Peggs KS, Thomson KJ, Singer M, Howell DC, Morris EC (2013). Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning.. Br J Haematol, 161(4), 578 - 586. doi:10.1111/bjh.12294
    • Stauss HJ, Morris EC (2013). Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.. Gene Ther, , - . doi:10.1038/gt.2013.34
    • Morris E, Gore M, Baker A, Thrasher AJ (2013). Moving forward on shifting sands: ethical regulation of gene therapy clinical trials in the United kingdom.. Mol Ther, 21(4), 715 - 716. doi:10.1038/mt.2013.43
    • Xue SA, Gao L, Ahmadi M, Ghorashian S, Barros RD, Pospori C, Holler A, Wright G, Thomas S, Topp M, Morris EC, Stauss HJ (2013). Human MHC Class I-restricted high avidity CD4(+) T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo.. Oncoimmunology, 2(1), e22590 - . doi:10.4161/onci.22590
    • Carpenter BJM, Ghorashain S, Nicholson E, Griffin J, Ahmadi M, Zhang L, Flutter B, Holler A, Stauss H, Morris E, Chakraverty R (2013). Over-expression of CXCR4 targets donor T-cells to tumour niches and enhances graft-versus-lymphoma.

    2012

    • Uttenthal BJ, Carpenter B, Ghorashian S, Wright GP, Flutter B, Xue SA, Chakraverty R, Morris EC (2012). Adoptive therapy with redirected MHC class I-restricted antigen-specific regulatory T cells is a potential novel cellular therapy for graft-versus-host disease.
    • Loosemore M, Walsh SB, Morris E, Stewart G, Porter JB, Montgomery H (2012). Sudden exertional death in sickle cell trait.. Br J Sports Med, 46(5), 312 - 314. doi:10.1136/bjsports-2011-090521
    • Carpenter B, Ghorashian S, Nicholson E, Griffin J, Ahmadi M, Zhang L, Holler A, Stauss H, Morris E, Chakraverty R (2012). Targeting therapeutic T cells to tumour niches.
    • Ghorashian S, Holler A, Flutter B, Xue S-A, Fallah-Arani F, Sivakumaran J, Bennett C, Morris E, Stauss HJ, Chakraverty R (2012). CD4 help can overcome tolerance developing in adoptively-transferred T cells transduced with a self-specific TCR.
    • Uttenthal BJ, Chua I, Morris EC, Stauss HJ (2012). Challenges in T cell receptor gene therapy.. J Gene Med, 14(6), 386 - 399. doi:10.1002/jgm.2637
    • Nicholson E, Ahmadi M, Thomas S, Holler A, Carpenter B, Xue SA, Stauss H, Morris E (2012). Enhancing the efficacy of T cell receptor (TCR) gene therapy by co-transfer of TCR and additional CD3 molecules into CD4+T cells.
    • Thomson KJ, Kottaridis P, Cassoni A, Morris EC, Khwaja A, Linch DC, Chakraverty R, Peggs KS, Mackinnon S (2012). ALLOGENEIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE MYELOID LEUKEMIA: NO INCREASE IN RELAPSE WITH ALEMTUZUMAB-DEPLETED GRAFTS.
    • Nicholson EK, Ahmadi M, Holler A, Pike R, Carpenter B, Thomas S, Ghorashian S, Xue S-A, Stauss H, Morris E (2012). Enhancing the Efficacy of T Cell Receptor (TCR) Gene Therapy by Co-Transfer of TCR and Additional CD3 Molecules Into CD4+T Cells.
    • Nicholson EK, Ahmadi M, Holler A, Pike R, Carpenter B, Thomas S, Ghorashian S, Xue S-A, Stauss H, Morris E (2012). Enhancing the Efficacy of T Cell Receptor (TCR) Gene Therapy by Co-Transfer of TCR and Additional CD3 Molecules Into CD4+T Cells.
    • Sive JI, Thomson KJ, Morris EC, Ward KN, Peggs KS (2012). Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults.. Clin Infect Dis, 55(10), 1362 - 1370. doi:10.1093/cid/cis689
    • Chua I, Ahmadi M, Xue S, Holler A, Zamoyska R, Stauss HJ, Morris EC (2012). Exploiting CD8 co-receptor to improve the function of genetically modified CD4 T cells for cancer immunotherapy.
    • Field A-C, Stauss HJ, Morris EC, Qasim W (2012). Comparison on lentiviral and Sleeping Beauty transposon-mediated gene expression of T cell receptor genes.
    • Chua I, Xue SA, Holler A, Maniusyte R, Zamoyska R, Stauss HJ, Morris EC (2012). Exploiting CD8 beta mutations which increase TCR avidity to improve the function of genetically modified T cells for immunotherapy.
    • Mohamedbhai SG, Edwards N, Morris EC, Mackinnon S, Thomson KJ, Peggs KS (2012). Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure.. Br J Haematol, 156(4), 516 - 522. doi:10.1111/j.1365-2141.2011.08944.x
    • Thaventhiran JE, McGovern N, Dickinson R, Bigley V, Doffinger R, Kumararatne D, Chee R, Seneviratne S, Grimbacher B, Collin M, Morris E (2012). IDENTIFICATION OF GATA-2 MUTATIONS USING A SIMPLE SCREENING PROCEDURE IN PATIENTS WITH PAPILLOMA VIRUS INFECTIONS.

    2011

    • Richardson S, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, Fielding A, Goldstone A, Kottaridis P, Morris E, Benjamin R, Peggs K, Thomson K, Vandenberghe E, Mackinnon S, Chakraverty R (2011). Risk-stratified adoptive cellular therapy following allogeneic haematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. British Jouurnal of Haematology, In press, - .
    • Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC, Hough R, Morris EC, Fielding A, Chakraverty R, Thomson KJ, Mackinnon S (2011). Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.. J Clin Oncol, 29(8), 971 - 978. doi:10.1200/JCO.2010.32.1711
    • Townsend W, Holroyd A, Pearce RM, Mackinnon S, Goldstone AH, Linch DC, Peggs KS, Thomson K, Singer M, Naik P, Howell D, Morris E (2011). A Simple Prognostic Score to Predict Short and Long-Term Survival Following ICU Admission in Critically III Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: Improved Survival Following Reduced Intensity Conditioning.
    • Nicholson E, Ahmadi M, Thomas S, Holler A, Carpenter B, Xue SA, Stauss H, Morris E (2011). Enhancing the efficacy of T cell receptor (TCR) gene therapy by co-transfer of TCR and additional CD3 molecules into CD4+T cells. HUM GENE THER, 22(10), A119 - A119.
    • Uttenthal BJ, Carpenter B, Ghorashian S, Wright GP, Flutter B, Xue S, Chakraverty R, Morris EC (2011). Adoptive therapy with redirected MHC class I-restricted antigen-specific regulatory T cells is a potential novel cellular therapy for graft-versus-host disease.
    • Nicholson EK, Ahmadi M, Thomas S, Carpenter B, Voisine C, Xue S, Stauss HJ, Morris EC (2011). Improving the function of TCR gene modified T-cells for adoptive immunotherapy: co-transfer of additional CD3 molecules enhances functional avidity of TCR-transduced CD4+ T-cells.
    • Peggs KS, Kayani I, Thomson K, Morris E, Kottaridis P, Ardeshna KM, Fielding A, Hough R, Goldstone AH, Chakraverty R, Linch DC, Mackinnon S (2011). Positive Pre-Transplantation ([18-F]) FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma.
    • Kothari J, Ljubic A, Peggs KS, Thomson K, Morris E, Virchis AE, Lambert J, Goldstone AH, Linch DC, Ardeshna KM (2011). Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure.
    • Ahmadi M, King J, Xue S-A, Voisine C, Holler A, Wright G, Waxman J, Morris E, Stauss H (2011). CD3 limits the efficacy of TCR gene therapy in vivo.
    • Xue SA, Gao L, Ahmadi M, Ghorashian S, Pospori C, Holler A, Thomas S, Morris E, Stauss HJ (2011). Generation of MHC-I restricted CD4+CMV and EBV specific T cells for the management of leukaemia patients. HUM GENE THER, 22(10), A73 - A73.
    • Chua I, Holler A, Xue SHA, Zamoyska R, Stauss HJ, Morris EC (2011). T cells expressing genetically modified CDS co-receptor have enhanced T cell effector function. HUM GENE THER, 22(10), A34 - A35.
    • Pospori C, Xue SA, Holler A, Voisine C, Perro M, King J, Fallah-Arani F, Flutter B, Chakraverty R, Stauss HJ, Morris EC (2011). Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. BLOOD, 117(25), 6813 - 6824. doi:10.1182/blood-2010-08-304568
    • Ahmadi M, King JW, Xue SA, Voisine C, Holler A, Wright GP, Waxman J, Morris E, Stauss HJ (2011). CD3 limits the efficacy of TCR gene therapy in vivo.. Blood, 118(13), 3528 - 3537. doi:10.1182/blood-2011-04-346338
    • Thomas S, Xue SA, Bangham CR, Jakobsen BK, Morris EC, Stauss HJ (2011). Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen.. Blood, 118(2), 319 - 329. doi:10.1182/blood-2010-12-326736
    • Thomson K, Kayani I, Ardeshna KM, Morris E, Hough R, Goldstone AH, Linch DC, Peggs KS (2011). Response-Adjusted Transplantation in Primary Resistant and Relapsed Hodgkin Lymphoma.

    2010

    • Pospori C, Xue SA, Holler A, Voisine C, Perro M, Fallah-Arani F, Flutter B, Chakraverty R, Stauss HJ, Morris EC (2010). Specificity for a tumor-associated self-antigen drives the development of functional memory T cells in the absence of vaccination.
    • Lambert JR, Bomanji JB, Peggs KS, Thomson KJ, Chakraverty RK, Fielding AK, Kottaridis PD, Roughton M, Morris EC, Goldstone AH, Linch DC, Ell PJ, Mackinnon S (2010). Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.. Blood, 115(14), 2763 - 2768. doi:10.1182/blood-2009-11-255182
    • Mackinnon S, Lambert J, Bomanji J, Peggs K, Thomson K, Chakraverty R, Fielding A, Kottaridis P, Roughton M, Morris E, Goldstone A, Linch D, Ell P (2010). Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplant for lymphoma.
    • Peggs KS, Thomson K, Morris E, Kottaridis P, Hough R, Goldstone A, Fielding A, Ardeshna K, Chakraverty R, Linch DC, Mackinnon S (2010). Donor lymphocyte infusions guided by PET-CT offer durable salvage in relapsed Hodgkin's lymphoma post-allogeneic transplantation.
    • Morris EC, Martinez-Davila I, Cellerai C, Chen F, Moss P, Khwaja A, Virchis A, Kottaridis P, Stauss HJ (2010). WT1 peptide vaccination in poor risk adult AML patients induces WT1-specific immune responses: Results of a leukaemia research supported phase I clinical trial, WTPV-001.
    • Ahmadi M, King J, Nicholson E, Morris E, Stauss H (2010). Enhancing the Efficacy of TCR Gene Therapy by Co-Transfer of CD3 Molecules.
    • Perro M, Tsang J, Xue SA, Escors D, Cesco-Gaspere M, Pospori D, Gao L, Hart D, Collins M, Stauss H, Morris EC (2010). Lentiviral Vectors for TCR Gene Transfer: Improved Function of TCR-Transduced T Cells After Non-Activating Cytokine-Mediated Transduction.
    • Perro M, Tsang J, Xue SA, Escors D, Cesco-Gaspere M, Pospori C, Gao L, Hart D, Collins M, Stauss H, Morris EC (2010). Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer.. Gene Ther, 17(6), 721 - 732. doi:10.1038/gt.2010.4
    • Cook G, Smith GM, Kirkland K, Lee J, Pearce R, Thomson K, Morris E, Orchard K, Rule S, Russell N, Craddock C, Marks DI, Clinical Trials Committee (CTC) of the British Society for Blood and Marrow Transplantation (BSBMT) (2010). Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.. Biol Blood Marrow Transplant, 16(10), 1419 - 1427. doi:10.1016/j.bbmt.2010.04.006
    • Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, Milligan D, Collin M, Crawley C, Johnson P, Clark A, Parker A, Bloor A, Pettengell R, Snowden J, Pettitt A, Clark R, Hale G, Peggs K, Thomson K, Morris E, Mackinnon S (2010). Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.. Blood, 116(16), 3080 - 3088. doi:10.1182/blood-2010-05-286856
    • Richardson S, Vandenberghe E, Benjamin R, Sudak J, Goldstone A, Thomson K, Morris E, Peggs K, Fielding A, Kottaridis P, MacKinnon S, Chakraverty R (2010). Reduced-intensity allografting with in vivo T-cell depletion is associated with a favourable outcome in chronic lymphocytic leukaemia.
    • Thomson K, Morris E, Milligan D, Parker A, Hunter A, Cook G, Bloor A, Clark F, Kazmi M, Linch D, Chakraverty R, Peggs K, Mackinnon S (2010). T-cell depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.
    • Mead A, Thomson KJ, Morris EC, Mohamedbhai S, Orti G, Chakraverty R, Linch DC, Mackinnon S, Peggs KS (2010). HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced intensity conditioning.
    • Field AC, Stauss HJ, Goulden N, Morris E, Qasim W (2010). Defining an Optimal Promoter for Lentiviral Gene Expression of T Cell Receptor Genes.
    • Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G, Bloor AJ, Clark F, Kazmi M, Linch DC, Chakraverty R, Peggs KS, Mackinnon S (2010). T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.. J Clin Oncol, 28(23), 3695 - 3700. doi:10.1200/JCO.2009.26.9100
    • Mead AJ, Thomson KJ, Morris EC, Mohamedbhai S, Denovan S, Orti G, Fielding AK, Kottaridis PD, Hough R, Chakraverty R, Linch DC, Mackinnon S, Peggs KS (2010). HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.. Blood, 115(25), 5147 - 5153. doi:10.1182/blood-2010-01-265413
    • Thomas S, Stauss HJ, Morris EC (2010). Molecular immunology lessons from therapeutic T-cell receptor gene transfer. IMMUNOLOGY, 129(2), 170 - 177. doi:10.1111/j.1365-2567.2009.03227.x
    • Ahmadi M, King J, Nicholson E, Morris E, Stauss H (2010). Enhancing the Efficacy of TCR Gene Therapy by Co-Transfer of CD3 Molecules.

    2009

    • KJ Thomson ECM, A Bloor GC, D Milligan AP, C Craddock LY, DC Linch RKC, KS Peggs ASM (2009). Favorable long-term survival following reduced intensity allogeneic transplantation for multiply relapsed aggressive non-Hodgkins Lymphoma.. Journal of Clinical Oncology, 27(3), 426 - 432.
    • (2009). Haematology Part 1 of 2. Medicine, 37(3), 119 - 178.
    • Peggs KS, Thomson K, Morris E, Chowdhry N, Verfuerth S, Kottaridis P, Goldstone AH, Ardeshna K, Linch D, Chakraverty R, Mackinnon S (2009). Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation.
    • Roddie C, Paul J, Benjamin R, Gallimore C, Xerry J, Gray JJ, Peggs K, Morris E, Thomson K, Ward K (2009). Allogeneic haematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognised cause of morbidity.
    • Holroyd A, Townsend W, Naik P, Mackinnon S, Howell D, Goldstone A, Linch D, Peggs K, Thomson K, Singer M, Morris E (2009). Favourable outcome for allogeneic haematopoietic transplant recipients requiring intensive therapy unit admission with improved survival following reduced intensity conditioning.
    • Thomson K, Kottaridis P, Morris E, Chakraverty R, Peggs K, Mackinnon S (2009). Successful myeloablative transplantation in high-risk acute myeloid leukaemia using unrelated donors with alemtuzumab for T-cell depletion.
    • Holroyd A, Townsend W, Naik P, Mackinnon S, Howell D, Goldstone A, Linch D, Peggs K, Thomson K, Singer M, Morris E (2009). Favourable outcome for haematopoietic transplant recipients requiring intensive therapy unit admission: a 10-year single-centre experience.
    • Pospori C, Cesco-Gaspere M, Xue S, Voisine C, Perro M, Holler A, Wright G, Stauss H, Morris E (2009). WT1-TCR gene transfer into haematopoietic stem cells: a tumour immunotherapy model.
    • Pospori C, Cesco-Gaspere M, Xue S, Voisine C, Perro M, Holler A, Wright G, Stauss H, Morris E (2009). WT1-TCR gene transfer into HSCs: a tumour immunotherapy model.
    • Morris E, Thomson KJ (2009). Bone marrow and stem cell transplantation. Medicine, 37(3), 168 - 171.
    • Orti G, Fielding A, Kottaridis P, Morris E, Thomson K, Lowdell M, Peggs K, Mackinnon S, Chakraverty R (2009). Phase I study of high-stringency CD8-depletion of donor leukocyte transfusions following allogeneic haematopoietic stem cell transplantation.. Transplantation, 88, 1312 - 1318.
    • (2009). Haematology Part 2 of 2. Medicine, 37(4), 179 - 222.
    • Cesco-Gaspere M, Morris E, Stauss HJ (2009). Immunomodulation in the treatment of haematological malignancies. Clinical and Experimental Medicine, 9(2), 81 - 92.
    • Roddie C, Paul J, Benjamin R, Gallimore CI, Xerry J, Gray JJ, Peggs KS M, E T, KJ W, KN (2009). Allogeneic haematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognised cause of morbidity.. Clinical Infectious Diseases, 49(7), 1061 - 1068.
    • Lowdell M, Morris E (2009). Recent advances in in clinical cellular immunotherapy. In Murphy MF, Pamphilon DH (Ed.), Practical Transfusion Medicine (pp. 462 - 468). : Wiley-Blackwell.

    2008

    • Orti G, Peggs K, Thomson K, Morris E, Lowdell M, Mackinnon S, Chakraverty R (2008). Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogencic Stem Cell Transplantation..
    • Mead AJ, Thomson KJ, Morris EC, Chakraverty R, Linch DC, Mackinnon S, Peggs KS (2008). Mismatch at 1-2 HLA Loci Does Not Reduce Survival Following Alemtuzumab-Based Reduced Intensity Unrelated Donor Allogeneic Transplantation.
    • Stauss HJ, Thomas S, Cesco-Gaspere M, Hart DP, Xue SA, Holler A, King J, Wright G, Perro M, Pospori C, Morris E (2008). WT1-specific T cell receptor gene therapy: Improving TCR function in transduced T cells. Blood Cells, Molecules, and Diseases, 40(1), 113 - 116. doi:10.1016/j.bcmd.2007.06.018
    • Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A PR, Milligan D MEC, Goldstone AH LDC, Mackinnon S (2008). Superiority of reduced intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin’s lymphoma following autologous stem cell transplantation.. Bone Marrow Transplantation, 41(9), 765 - 770.
    • Kottaridis P, Thomson K, Cassoni A, Pearce R, Chakraverty R, Morris E, Peggs K, Mackinnon S (2008). Myeloablative allogeneic stem cell transplantation with unrelated donors for high-risk acute myeloid leukaemia: no increase in relapse with alemtuzumab-depleted grafts.
    • Mackinnon S, Morris EC, Bloor A, Cook G, Milligan D, Parker A, Craddock C, Yung L, Linch DC, Chakraverty RK, Peggs KS, Thomson KJ (2008). Favourable long-term survival following reduced intensity allogeneic transplantation for multiply relapsed aggressive non-Hodgkins lymphoma.
    • Mackinnon S, Morris EC, Bloor A, Cook G, Milligan D, Parker A, Craddock C, Yung L, Linch DC, Chakraverty RK, Peggs KS, Thomson KJ (2008). Excellent long-term survival following reduced intensity allogeneic transplantation for multiply relapsed follicular lymphoma.
    • Hart DP, Thomas S, Xue S, Stauss HJ, Morris EC (2008). LMP2-specific TCR gene therapy for Hodgkin's lymphoma.
    • Thomson KJ, Peggs KS, Smith P, Cavet J, Hunter A, Parker A, Pettengell R, Milligan D, Morris EC, Goldstone AH, Linch DC, Mackinnon S (2008). Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. BONE MARROW TRANSPL, 41(9), 765 - 770. doi:10.1038/sj.bmt.1705977
    • Hart DP, Xue SA, Thomas S, Cesco-Gaspere M, Tranter A, Willcox B, Lee SP, Steven N, Morris EC, Stauss HJ (2008). Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells.. Gene Therapy, 15(8), 625 - 631. doi:10.1038/sj.gt.3303078

    2007

    • Hart DP, Thomas S, Xue SA, Morris EC, Stauss HJ (2007). LMP2-specific TCR gene therapy for Hodgkin lymphoma - Design of a dominant TCR construct for immunotherapy.
    • Thomson K, Morris E, Bloor A, Cook G, Milligan D, Parker A, Craddock C, Yung L, Chakraverty R, Peggs K, Mackinnon S (2007). Long-term follow-up of reduced intensity transplantation with an alemtuzumab-containing regimen for aggressive non-Hodgkins lymphoma.
    • Thomas S, Xue SA, Cesco-Gaspere M, San Jose E, Hart D, Morris E, Stauss H (2007). Targeting the Wilms Tumour antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. The Journal of Immunology, 179(9), 5803 - 5810.
    • Chakraverty R, Manji N, Clark R, Crawley C, Johnson P, Liakopoulou E, Marsh J, Milligan D, Morris E, Peggs K, Thomson K, Snowden J, Jackson G, Mackinnon S (2007). Multi-center phase II study of CAMPATH-1H dose de-escalation prior to nonmyeloablative HLA-identical sibling transplantation.
    • Thomson K, Morris E, Milligan D, Hunter A, Cook G, Bloor A, Craddock C, Yung L, Parker A, Chakraverty R, Peggs K, Mackinnon S (2007). Extended follow-up of reduced intensity transplantation with an alemtuzumab-containing regimen for follicular lymphoma.
    • Stauss HJ, Cesco-Gaspere M, Thomas S, Hart DP, Xue SA, Holler A, Wright G, Perro M, Little AM, Pospori C, King J, Morris EC (2007). Monoclonal T-cell receptors: new reagents for cancer therapy. Molecular Therapy, 15(10), 1744 - 1750.
    • Morris E, Hart DP, King J, Thomas S, Cesco-Gaspere M, Xue SA, Stauss HJ (2007). Immunotherapy of Leukaemia with TCR gene modified T cells. Hematology Education: The education program for the annual congress of the European Hematology Association, 1(1), 264 - 268.

    2006

    • Morris E, Hart D, Gao LQ, Tsallios A, Xue SA, Stauss H (2006). Generation of tumor-specific T-cell therapies. BLOOD REV, 20(2), 61 - 69. doi:10.1016/j.blre.2005.05.001
    • Emma C Morris DPH, Judy King ST, Michela Cesco-Gaspere S-AXAHJS (2006). Immunotherapy of leukaemia with TCR gene modified T cells.. Hematology Education: The education program for the annual congress of the European Hematology Association, 1, 264 - 268.

    2005

    • Thomson KJ, Peggs KS, Morris EC, Khwaja A, Linch DC, Goldstone AH, Mackinnon S (2005). Allogeneic stem cell transplantation with T cell depletion for acute myeloid leukaemia.
    • Xue S, Gao L, Hart D, Gillmore R, Qasime W, Thrasher A, Uckert W, Morris E, Stauss H (2005). Development of WT1-specific CTL for the treatment of human leukemia through TCR gene transfer.
    • Mansour MR, Dogan A, Morris EC, Khwaja A, Linch DC, Mackinnon S, Peggs KS (2005). Allogeneic transplantation for hepatosplenic alphabeta T-cell lymphoma.. Bone Marrow Transplant, 35(9), 931 - 934. doi:10.1038/sj.bmt.1704897
    • Xue SA, Gao LQ, Hart D, Gillmore R, Qasim W, Thrasher A, Apperley J, Engels B, Uckert W, Morris E, Stauss H (2005). Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood, 106(9), 3062 - 3067. doi:10.1182/blood-2005-01-0146
    • Xue SA, Gao LQ, Hart D, Gillmore R, Qasim W, Thrasher A, Apperley J, Engels B, Uckert W, Morris E, Stauss H (2005). Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. BLOOD, 106(9), 3062 - 3067. doi:10.1182/blood-2005-01-0146
    • Mansour MR, Dogan A, Morris EC, Khwaja A, Linch DC, Mackinnon S, Peggs KS (2005). Allogeneic transplantation for hepatosplenic allphabeta T-cell lymphoma.. Bone Marrow Transplantation, 35(9), 824 - 829.
    • Thomson KJ, Peggs KS, Morris EC, Khwaja A, Linch DC, Goldstone AH, Mackinnon S (2005). Allogeneic stem cell transplantation for high-risk acute myeloid leukemia: No increase in relapse with alemtuzumab-depleted grafts..
    • Morris EC, Mackinnon S (2005). Reduced Intensity Allogeneic Stem Cell Transplantation for Low Grade Non-Hodgkin's Lymphoma. Best Practice and Research Clinical Haematology, 18(1), 129 - 142.
    • Xue S, Gillmore R, Downs A, Tsallios A, Holler A, Gao L, Wong E, Morris E, Stauss HJ (2005). Exploiting T cell receptor genes for cancer immunotherapy. Clinical and Experimental Immunology, 139, 167 - 172.
    • Morris EC, Tsallios A, Bendle GM, Xue SA, Stauss HJ (2005). A critical role for TCR-transduced MHC class I-restricted helper T cells in long-term tumor protection.. Proceedings of the National Academy of Sciences of the United States of America, 102(22), 7934 - 7939. doi:10.1073/pnas.0500357102
    • Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, Craddock C, Pettengell R, Morris E, Hale G, Waldmann H, Goldstone AH, Linch DC, Mackinnon S (2005). Clinical evidence of a graft versus Hodgkin's Lymphoma effect following reduced intensity allogeneic transplantation.. The Lancet, 365(9475), 1934 - 1941. doi:10.1016/S0140-6736(05)66659-7
    • Hart DP, Avivi I, Thomson KJ, Peggs KS, Morris EC, Goldstone AH, Linch DC, Ell PJ, Bomanji JB, Mackinnon S (2005). Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions.. Br J Haematol, 128(6), 824 - 829. doi:10.1111/j.1365-2141.2005.05388.x
    • Morris EC, Tsallios A, Bendle G, Xue S, Stauss HJ (2005). Functional analysis of TCR-transduced MHC class I-restricted helper T cells and their role in tumor protection. IMMUNOLOGY, 116, 32 - 32.
    • Tsallios A, Stauss HJ, Morris EC (2005). MHC class 1-restricted CD4+ helper T cells augment CD8+ cytotoxic T cell mediated anti-tumour immunity.
    • Hart DP, Morris EC, Stauss HJ (2005). Effect of Interleukin 15 on human, antigen-specific CD8+T cells.
    • Morris E, Hart D, Tsallios A, Xue SA, Stauss HJ (2005). Generation of tumour-specific T-cell therapies. Blood Reviews, (June 21), - .
    • Morris E, Mackinnon S (2005). Outcome following alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for relapsed and refractory Non-Hodgkin's Lymphoma (NHL).. Transfusion and Apheresis Science, 32(1), 73 - 83.
    • Hart DP, Avivi I, Thomson KJ, Peggs KS, Morris EC, Goldstone AH, Linch DC, Ell PJ, Bomanji JB, McKinnon S (2005). Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions.. British Journal of Haematology, 128(6), 824 - 829.

    2004

    • Stauss HJ, Xue S, Gillmore R, Gao L, Bendle G, Holler A, Downs AM, Morris E (2004). Exploiting alloreactivity for tumour immunotherapy.. Vox Sanguinis, 87(suppl 2), 227 - 229.
    • Mackinnon S, Thomson K, Morris E, Kottaridis P, Peggs K (2004). Reduced intensity transplantation: where are we now?. THE HEMATOLOGY JOURNAL, 5(Suppl 3), S34 - S38.
    • Hart DP, Thomson KJ, Bannerjee L, Morris EC, Linch DC, Goldstone AH, Peggs KS, Mackinnon S (2004). Very low dose aciclovir prophylaxis postallogeneic stem cell transplantation prevents varicella zoster infection without development of clinically relevant resistance.
    • Xue S, Gillmore R, Gao L, Bendle G, Holler A, Downs AM, Tsallios A, Ramirez F, Ghani Y, Hart D, Alcock S, Tranter A, Morris E, Stauss HJ (2004). Use of the allogeneic repertoire to enhance anti-tumor immunity.. Journal of Biological Regulators and Homeostatic Agents, 18(1), 131 - 133.
    • Tsallios A, Xue S, Stauss HJ, Morris EC (2004). CD8-independent, MHC class I-restricted antigen recognition by murine CD4 T cells via transferred T-cell receptors.
    • Peggs KS, Thomson K, Hart DL, Geary J, Morris E, Yong K, Goldstone A, Linch D, Mackinnon S (2004). Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood, 103(4), 1548 - 1556. doi:10.1182/blood-2003-05-1513
    • Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S (2004). Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. BLOOD, 104(13), 3865 - 3871. doi:10.1182/blood-2004-03-1105
    • Mackinnon S, Thomson K, Morris E, Kottaridis PD, Peggs KS (2004). Reduced intensity transplantation: where are we now?. Hematol J, 5 Suppl 3, S34 - S38. doi:10.1038/sj.thj.6200419
    • Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S (2004). Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood, 104(13), 3865 - 3871. doi:10.1182/blood-2004-03-1105
    • Xue S, Gao L, Gillmore R, Bendle G, Holler A, Downs AM, Tsallios A, Ramirez F, Ghani Y, Hart D, Alcock S, Tranter A, Stauss HJ, Morris E (2004). WT1-targeted immunotherapy of leukaemia.. Blood Cells, Molecules, and Diseases, 33(3), 288 - 290.

    2003

    • Hart DP, Avivi I, Thomson KJ, Goldstone AH, Linch DC, Ell PJ, Bomanji JB, Morris EC, Peggs KS, Mackinnon S (2003). Use of Positron Emission Tomography following reduced intensity allograft for Hodgkin and Non Hodgkin Lymphoma to guide Donor Lymphocyte Infusion administration..
    • Hart DP, Thomson KJ, Bannerjee L, Morris EC, Linch DC, Goldstone AH, Peggs KS, Mackinnon S (2003). Very low dose aciclovir prophylaxis post allogeneic stem cell transplantation prevents varicella zoster infection without development of clinically relevant resistance..
    • Morris EC, Bendle GM, Stauss HJ (2003). Prospects for immunotherapy of malignant disease. Clin Exp Immunol, 131, 1 - 7.
    • Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH, Mackinnon S, Hale G (2003). Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications.. Blood, 102(1), 404 - 406. doi:10.1182/blood-2002-09-2687
    • Duarte RF, Morris EC, Shaw BE, Thomson KJ, Ethell M, Peggs KS, Potter MN, Mackinnon S (2003). Recipient CMV seropositivity may adversely affect the outcome of unrelated donor transplantation by increasing the risk of disease relapse..
    • Sen S, Jalan R, Morris EC, Steiner C, MACKINNON S, Williams R (2003). Reversal of severe cholestasis caused by chronic graft-versus-host disease with the MARS liver-support device. Transplantation, 75, 1766 - 1767.
    • Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriacou C, Goldstone AH, Mackinnon S, Hale G (2003). Pharmacokinetics of alemtuzumab (CAMPATH-1H) used for in vivo and in vitro T-cell depletion in allogeneic transplants: relevance for early adoptive immunotherapy and infectious complications. BLOOD, 102, 404 - 406. doi:10.1182/blood-2002-09-2687
    • Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriacou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K (2003). Reduced intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-senstive myeloma: limited efficacy of graft-versus-tumor activity.. Biology of Blood and Marrow Transplantation, 9(4), 257 - 265. doi:10.1053/bbmt.2003.50009
    • Morris EC, Harrison G, Bailey CC, Hann IM, Gibson BE, Richards S, Webb DK (2003). Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemia.. British Journal of Haematology, 120, 787 - 789.
    • Morris EC, Dafforn T R F, S L MMA, Horvath AJ, Hampson L, Hampson IN, Currie G, Carrell RW, Coughlin PB (2003). Murine Serpin 2A is a redox sensitive intracellular protein. Biochemical Journal, 371, 165 - 173.
    • Thomson K, Hart D, Cook G, Milligan D, Parker A, Marsh J, Chopra R, Littlewood T, Linch D, Goldstone A, Morris E, Hale G, Peggs K, Mackinnon S (2003). Lowering the dose of in vivo alemtuzumab (Campath-1H) in reduced intensity conditioning for allogeneic transplantation results in more graft-versus-host disease..

    2002

    • Naik P, Morris E, Mackinnon S, Singer M (2002). Do critically ill patients with haematological malignancy survive intensive care and beyond?. BRIT J ANAESTH, 89(2), 359P - 359P.
    • Peggs KS, Thomson K, Geary J, Morris E, Kottaridis P, Watts M, Yong K, Linch DC, Goldstone AH, Mackinnon S (2002). Dose escalating donor lymphocyte infusions (DLI) following T-depleted reduced intensity allografting: High response rates associated with conversion to full donor chimerism (FDC) are not durable despite persistent donor chimerism..
    • Peggs KS, Morris EC, Kottaridis PD, Geary J, Goldstone AH, Linch DC, Mackinnon S (2002). Conditioning regimen may influence outcome of ABO incompatible non-myeloablative haemtopoietic allogeneic stem cell transplantation.. Blood, 99, 4642 - 4644.

    2001

    • Peggs K, Kottaridis P, Morris E, Kyriacou C, Geary J, Yong K, Goldstone A, Linch D, Mackinnon S (2001). Escalating dose donor lymphocyte infusions following non-myeloablative allogeneic transplantation are associated with minimal toxicity with sibling donors but a significant risk of severe GVHD with unrelated donors..
    • Morris E, Rebello P, Thomson K, Peggs K, Kyriakou C, Goldstone A, Linch D, Mackinnon S, Hale G (2001). Pharmacokinetics of Campath-1H in vivo T cell depletion in non-myeloablative allogeneic transplants: Relevance for early adoptive immunotherapy..
    • Morris E, Naik P, Goldstone A, Linch D, Mackinnon S, Singer M (2001). 5 year experience of intensive care for critically ill patients following chemotherapy or bone marrow transplantation: Who should go to ICU?. BLOOD, 98(11), 432A - 433A.
    • Morris EC, Carrell RW, Coughlin PB (2001). Intracellular serpins in haemopoietic and peripheral blood cells. BRIT J HAEMATOL, 115(4), 758 - 766.

    • Gordon-Smith EC, Morris E (). Haematopoietic Stem Cell Transplantation. In Weatherall DG, Ledingham JGG, Warrell DA (Ed.), Oxford Textbook of Medicine (pp. - ). : Oxford University Press.
    • Xue SA, Gao L, Thomas S, Hart DP, Xue JZ, Gillmore R, Voss RH, Morris E, Stauss HJ (). Development of a WT1-TCR for clinical trials: engineered patient T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica, , - . doi:10.3324/haematol.2009.006486
    • Ghorashian S, Carpenter B, Holler A, Nicholson E, Ahmadi M, Zech M, Bennett C, Xue S, Morris E, Stauss H, Chakraverty R (). CD4 Cells Engineered to Express an MHC Class I Restricted TCR Can Rescue CD8 Cells Tolerized to Tumour-Associated Antigens.
    • Carpenter B, Ghorashian S, Nicholson E, Griffin J, Ahmadi M, Holler A, Flutter B, Edwards N, Stauss H, Morris E, Chakraverty R (). Targeting Therapeutic T Cells to Tumour Niches.